Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.53 +3.09%

+$0.08 today

Market cap
$297.72M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.25M

Average 3.81M

ALT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Altimmune, Inc.NASDAQ: ALT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $16.17M rose 2.2% year over year, ahead of the -12.8% change in trailing-twelve-month research & development. Sequentially, it fell 12.2% from the prior quarter. Over 3 fiscal years it compounded at -2.0% a year.

Context

  • Research & development amounted to 162029.3% of revenue in FY2025, down 249100.7 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2.2% holds above the trailing-twelve-month pace of -12.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.17M-12.2% QoQ
Last fiscal yearDec 2025
$66.43M-19.2% YoY
LTMMar 2026
$66.77M-12.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.2%——
1 year-19.2%——
3-year CAGR-2.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
66.43M USD
Year-over-year change
-19.2%
4-year CAGR
-2.8%

Research & Development vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -12.8% is the 4th highest of 9, against a peer median of -16.1%.
  • Research & development amounts to 185483.3% of revenue for ALT, versus a peer median of 131.9%.
ALT Competitors
Research & Development for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$446.24M USD-15.0%-3.0%681.3%
GPCRStructure Therapeutics Inc.LTM Jun 2026$294.44M USD+79.9%+83.9%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M USD-20.8%-13.4%131.9%
IVAInventiva S.A.FY2025€83.61M EUR-8.0%+11.4%1865.0%
ALTAltimmune, Inc.LTM Mar 2026$66.77M USD-12.8%-2.0%185483.3%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$64.86M USD+10.1%-2.5%91.2%
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M USD-55.0%-0.4%—
ABUSArbutus Biopharma CorporationLTM Mar 2026$20.4M USD-57.1%-33.1%10.7%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$7.02M USD-17.1%+13.9%—
Peer median (excluding ALT) —-16.1%-1.5%131.9%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.41M(68K)426K20K41K
Cost of Revenue00000
Gross Profit4.41M(68K)426K20K41K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development74.54M70.54M65.8M82.23M66.43M
Selling, General & Admin15.41M17.13M18.14M20.97M28.1M
Operating Expenses101.32M87.67M96.36M103.19M94.53M
Depreciation & Amortization551K493K477K238K112K
EBITDA(96.53M)(84.41M)(87.94M)(94.81M)(87.03M)
EBITDA Margin-2189.0%124130.9%-20642.0%-474060.0%-212258.5%
Operating Income(96.91M)(87.74M)(95.93M)(103.17M)(94.49M)
Operating Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%
Interest Income203K2.87M7.35M8.07M7.54M
Interest Expense5K8K35K9K1.64M
Other Income / Expenses(176K)2.83M7.48M8.11M5.72M
Income Before Tax(97.09M)(84.91M)(88.45M)(95.06M)(88.77M)
Pre-Tax Margin-2201.6%124867.6%-20762.2%-475295.0%-216522.0%
Income Tax Expense0(197K)00(681K)
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Net Margin-2201.6%124577.9%-20762.2%-475295.0%-214861.0%
EPS (Basic)(2.35)(1.81)(1.66)(1.34)(1.00)
EPS (Diluted)(2.35)(1.81)(1.66)(1.34)(1.00)
Weighted Avg Shares41.28M46.93M53.25M71M88.1M
Weighted Avg Shares (Diluted)41.28M46.93M53.25M71M88.1M

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.